Programme data have reported, for example, higher mean weight loss at 72 weeks with a GIP/GLP-1 regimen than with some GLP-1-only arms at different time pointscontext, population, and rescue/adherence rules all matter
In a phase 2 randomised controlled trial involving adults without diabetes and with a BMI of 27 kg/m 2 and above, survodutide administered once weekly for 46 weeks led to dose-dependent weight loss
Because of their targeted effects, peptides can be used to support a wide variety of health goals, including: Fat Loss & Body Composition Lean physical performance and athletic recovery Deeper, more restorative sleep Cognitive function and mental clarity Anti-aging and cellular repair Improved skin tone and elasticity At Aspire Rejuvenation in Pittsburgh, we use clinically studied peptides to address these goals in a safe, strategic, and medically guided way
How we got here The timeline, start to now Category 2 of its interim 503A bulk drug substances list, blocking licensed pharmacies from compounding them
Acknowledgements This work was supported by the Novo Nordisk Foundation CO 2 Research Center (CORC) with grant number NNF21SA0072700 to N.L
The FDA has long taken a similar approach to 503A compounding with Category 1 bulks